So, if in 2018 Opko took a $2.9M charge to write d

Quote:

---

So, if in 2018 Opko took a $2.9M charge to write down their 29% investment in IncellDX...that means they basically took a 50% hit on their initial $6M investment made in 2012.

How does that affect the valuation of IncellDX?

---

In 2018 that would put the valuation at $10.32 million. I think Patterson was claiming 1 or 2,000 patients in longhaulers but the earnings on test kits and consultations would be negligible. As overcrowded as the diagnostic test market is the earnings from longhaulers could easily be offset by losses in other diagnostic tests.

An alignment with Cytodyn and leronlimab would have proven to be a goldmine for him but instead he got impatient and greedy. It may be in the best interest of IncellDX shareholders to unseat him from power.